Neurodegenerative Diseases Flashcards

1
Q

What is Neurodegeneration?

A
  • Collective term for diseases characterised by the death of neurons
  • Can be selective for particular classes of cells or more generalised

Examples include:
* Alzheimer’s
* Parkinson’s
* Huntington’s
* Amyotrophic lateral sclerosis (MND, lou Gherigs)
* MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What do neurons lost correlate to?

A
  • Symptoms reflect neurons lost.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is ALS?

A
  • Selective loss of motor neurons in cortex, brainstem and spinal cord
  • Several clinical subsets of ALS can be distinguished by anatomical location first affected
  • Progressive loss of muscle control till loss of respiratory function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is Alzheimer’s?

A
  • Loss of cholinergic and adrenergic nuclei in brainstem
  • Widespread, progressive loss starting in hippocampus and entorhinal cortex
  • Memory and learning impairments, leading to severe dementia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is Parkinson’s?

A
  • Loss of dopaminergic neurons in substantia nigra
  • Defects in motor control and coordination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the mechanisms of neurodegeneration?

A
  • Complex and multifactorial
  • Many hypotheses, little actual drug development

Some common hallmarks:
* Aggregation of misfolded proteins
* Neuroinf
* Reactive gliosis
* Vulnerability to oxidative or metabolic stress
* Sporadic and hereditary froms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is protein misfolding and aggregation?

A
  • Several neuronal proteins can become misfolded, expressed in abnormal forms, or incorrectly processed
    1. Tau, b-amyloid, a-synuclein, Huntingtin
  • These misfolded proteins can form aggregates
  • Reactive gliosis and neuroinf often reuslt
  • Calssic example is Alzheimer’s senile plaque
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is seeding and the spread of misfolded proteins?

A
  • Protein monomers can aggregate randomly, or form oligomers and fibrils that can spread between cells and brain regions
  • Analogous to prions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the Huntington’s disease mechanism?

A
  • Clear genetic component–Dominant autosomal allele
  • Polyglutamine repeat addedto huntintin protein
  • Degeneration of neurons in basal ganglia (especiallu caudate nucleus and putamen)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the symptoms of Huntington’s?

A
  • Memory lapses
  • Difficulty conc
  • Involuntary movts
  • Mood swings, depression
  • Loss of motor control
  • Personality changes
  • Onset around 30-50 years old and symptoms get progressively worse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the treatments for Huntington’s?

A
  • No available treatments to alter course of disease
  • Focus on alleviation of symptoms
  • Antidepressants
  • Lifestyle changes etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the mechanism for Alzheimer’s?

A
  • Senile plques (b-amyloid)
  • Neurofibrillary tangles (tau)
  • Reduced acetylcholine transmission
  • Glutamate-induced excitotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are treatments for Alzheimer’s?

A
  • AChE inhibitors:
    1. Prolong acetylcholine synaptic transient
    2. Inc tonic ACh
  • Memantine (NMDA rec antagonist)
    1. Block NMDAR Ca-permeable pore
    2. Reduces excitotoxicity
  • Antidepressants and antipsychotics
    1. Manage symptoms of worsening dementia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are plaque busting drugs?

A
  • New monoclonal antibody treatments that clear b-amyloid aggregates
  • Several ongoing trials
  • Red rate of clinical decline
  • Modes results (Best so far ~32% red in decline)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the mechanism for Parkinson’s?

A
  • Lewy bodies
  • Loss of nigrostratal neurons
  • Vulnerability to excitotoxicity
  • Compromised dopamine transmission in stiatum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the Extrapyrimidal motor system?

A
  • Control of involuntary movt, reflexes and posture
  • Multiple centres (striatum, cerebellum, thalamus etc)
  • Dopamine projections from substantia nigra to caudate nucleus and putamen key regulatory mechanism
17
Q

What are the symptoms of Parkinson’s?

A

Motor coordination deficits:
* Tremor
* Slow movement
* Rigidity

Other symptims:
* Genitourinary problems
* Constipation
* Dizziness
* Depression, anxiety
* Dementia

18
Q

What is the treatment for Parkinson’s?

A
  • Enhance dopamine transmission to compensate for loss of striatal dopamine
  • L-DOOA
  • Improves symptoms in short term but long term problems
  • LID (levodopa induced dyskinesia)
19
Q

What are the Levodopa pharmacokinetics?

A
  • Co-admin with benserazide or carbidopa
  • Prev bdown of levodopa by peripheral L-DOPA decarboxylase enzymes
  • Do not cross BBB
  • Improves pharmacokinetics of levodopa
20
Q

What is treatment for parkinson’s?

(Dopamine receptor agonists)

A

Dopamine receptor agonists:
* Direct activation of (Primarily) D2 receptors in basal ganglia
* Compensates for loss of nigrostriatal input
* Apomorphine (D1 & D2), bromocriptine, ropinirole, pramipexole

21
Q

What are side effects of Dopamine receptor agonists?

A
  • Hallucinations and delusions
  • Compulsive an impulsive behaviour
  • Activation of mesolimbic and mesocortical targets
22
Q

What are other methods of treating parkinson’s?

(Monoamine oxidase B inhibitors)

A
  • Block breakdown of dopamine
  • Less effective than other treatments
  • Usually used in conjunction with DR agonist and/or L-DOPA
23
Q

Why are neurodegenarative disease a problem?

A
  • Ageing pop=growing incidence
  • Inc prevalence of dementia
  • Disease burden growing
  • Clinical trials disappointing